Taurine and Aging: Hypothesis, Clinical Trial Data, and the 2025 Scientific Debate

Why did taurine become a focus of attention?

Taurine is a sulfur-containing amino acid synthesized in the body from cysteine and methionine, and also obtained from food (meat, seafood, dairy). In 2023, Singh and colleagues published a large-scale study in Science using mice, monkeys, and humans. Cross-sectional analysis of blood samples showed that 60-year-olds have taurine levels roughly one-third those of 5-year-olds. C57BL/6 mice supplemented with taurine from mid-life showed a median lifespan increase of approximately 12% in females and 10% in males. Reflexive activity, bone density, fat metabolism, and immune markers in middle-aged monkeys also improved with supplementation.

The hypothesis was compelling: if taurine declines with age and its restoration extends animal lifespan, then this deficiency is driving the aging clock. The publication sparked a wave of interest in supplementation.

What was challenged in 2025?

In 2025, the Fernandez group (NIH, National Institute on Aging) published in the same journal Science an analysis of three independent human cohorts, longitudinal mouse data, and primate data. Their conclusion: in healthy adults, taurine levels do not decline with age — they remain stable or even increase slightly. The apparent decline in the original paper was attributed primarily to the childhood-adolescent period and potential confounders from pooling heterogeneous samples.

In parallel, Marcangeli and colleagues (Aging Cell, 2025) measured taurine levels in 137 men aged 20 to 93 using isotope dilution — finding neither an age-related association nor any link to muscle mass, strength, physical performance, or insulin resistance. No significant decline in plasma levels between younger and older participants was detected.

This does not disprove the mouse data, but it breaks the chain of "deficiency in humans → a problem that needs to be corrected with supplementation."

What does taurine do in the cell?

Independently of the aging debate, taurine has well-characterized biochemical functions. It is incorporated into mitochondrial transfer RNAs and is required for correct translation of mitochondrially encoded proteins. Impairment of this function is linked to mitochondrial dysfunction. Taurine participates in cellular osmoregulation, bile acid conjugation, antioxidant defense, and suppression of cellular senescence. The Singh et al. study showed that supplementation reduced markers of cellular senescence, DNA damage, and mTOR activation in animals — the mechanisms are compelling, but derived from mice.

What do the clinical data in humans show?

A meta-analysis of 25 randomized controlled trials involving 1024 participants (Tzang et al., Nutrition & Diabetes, 2024) identified significant metabolic effects at doses of 0.5–6 g/day:

• Systolic BP: −4.0 mmHg (95% CI: −7.3 to −0.7; p=0.017)
• Diastolic BP: −1.5 mmHg (95% CI: −2.5 to −0.5; p=0.002)
• Triglycerides: −18.3 mg/dL (95% CI: −25.6 to −11.0; p<0.001)
• Total cholesterol: −8.3 mg/dL (95% CI: −13.8 to −2.9; p=0.003)
• LDL: −6.5 mg/dL (95% CI: −10.9 to −2.1; p=0.004)
• HOMA-IR (insulin resistance): −0.693 (95% CI: −1.133 to −0.252; p=0.002)

Body weight and BMI did not change significantly. A dose-response relationship was confirmed for diastolic BP and fasting glucose. Adverse events did not differ from placebo (OR=1.481, p=0.172); all cases were mild and transient.

In a separate randomized trial in people with pre-hypertension, 1.6 g/day of taurine over 12 weeks reduced systolic BP by 7.2 mmHg. The ongoing TauAge trial (Technical University of Munich, 137 participants, 4 g/day, 6 months) is examining effects on biological age using proteomic and epigenetic clocks — results are pending.